Does HMSA Cover Weight Loss Treatment in Hawaii? A 2026 Guide

Last updated: July 16, 2026

CVS Caremark Update — October 1, 2026: HMSA uses CVS Caremark as its pharmacy benefit manager (PBM). Zepbound (tirzepatide), which was temporarily removed from many CVS Caremark commercial formularies, is being reinstated effective October 1, 2026. Hawaii members with HMSA coverage may now find Zepbound available again at Tier 3–4, subject to prior authorization. Verify your specific plan’s formulary at cvs.com or call HMSA at 1-800-776-4672.

If you are exploring weight loss treatment options, Klarity Health connects you with licensed providers who may prescribe FDA-approved weight loss medications online.

Does HMSA Cover Weight Loss Treatment in Hawaii?

HMSA (Hawaii Medical Service Association), the state’s largest health insurer and an independent licensee of the Blue Cross Blue Shield Association, may cover a range of weight loss services for eligible members in 2026. Whether your plan covers prescription GLP-1 medications like Wegovy or Zepbound, behavioral weight loss counseling, or bariatric surgery will depend on your specific plan design, your employer’s benefit decisions, and whether medical necessity criteria are met.

This guide explains how HMSA’s CVS Caremark formulary handles weight loss medications in 2026, what prior authorization criteria typically apply, how Hawaii’s parity and benefit laws affect weight loss coverage, and how to verify your specific benefits before starting treatment.

HMSA Weight Loss Medication Formulary (CVS Caremark, 2026)

HMSA administers pharmacy benefits through CVS Caremark. The table below reflects how weight loss medications are typically tiered on CVS Caremark commercial formularies in 2026. Always verify your exact plan’s formulary at cvs.com or by calling CVS Caremark at 1-866-488-4708, as tier placement varies by plan.

Note: Tier placement and prior authorization requirements may vary by plan. Self-funded employer plans administered by HMSA may use different formulary designs. Always verify your specific benefits before starting treatment.

Prior Authorization Criteria for Weight Loss Medications

Most GLP-1 weight loss medications on HMSA’s CVS Caremark formulary require prior authorization. Based on standard CVS Caremark PA criteria in 2026, approval typically requires:

• BMI documentation: BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea, or cardiovascular disease)
• FDA-approved indication: Prescription must be for a medication’s approved weight management indication (e.g., Wegovy or Zepbound, not Ozempic or Mounjaro for weight loss)
• Lifestyle counseling: Documentation of concurrent enrollment in or referral to a structured behavioral weight loss program or counseling
• Step therapy: Some plans require a documented trial of an older agent (such as orlistat or Contrave) before authorizing Wegovy or Zepbound
• Absence of contraindications: History of medullary thyroid carcinoma or MEN2 (for semaglutide/tirzepatide) may result in denial
• Continued response for reauthorization: Annual reauthorization typically requires documented weight loss of ≥5% body weight within the first 16 weeks of therapy

To submit a prior authorization request for HMSA pharmacy benefits, providers may use the prc.hmsa.com portal or call the HMSA/CVS Caremark PA line at 1-866-488-4708. Standard PA decisions are typically made within 2–3 business days; urgent requests within 24–72 hours.

Zepbound Reinstated on CVS Caremark — October 1, 2026

One of the most significant formulary changes affecting HMSA members in 2026 is the reinstatement of Zepbound (tirzepatide) on CVS Caremark commercial formularies, effective October 1, 2026. Zepbound was temporarily removed from many CVS Caremark tiers earlier in 2025, leaving members who had started tirzepatide for weight loss without formulary coverage.

With the October 1 reinstatement, HMSA members on CVS Caremark commercial plans may once again access Zepbound at Tier 3–4 with prior authorization. Members who were previously denied Zepbound coverage due to the formulary removal may wish to resubmit a prior authorization request after October 1, 2026.

Key distinctions to be aware of:

• Zepbound vs. Mounjaro: Zepbound (tirzepatide) is the FDA-approved weight management formulation. Mounjaro (tirzepatide) is the diabetes formulation. Plans may cover Mounjaro at a different tier or deny it for weight loss use. Ensure the prescription specifies Zepbound for weight management.
• Cigna/ESI members: Express Scripts (Cigna’s PBM) did not remove Zepbound — Cigna members with ESI have had continuous Tier 3–4 access. The reinstatement news applies specifically to CVS Caremark plans (including HMSA).
• Medicare GLP-1 Bridge: The CMS Medicare GLP-1 Bridge ($50/month for Wegovy, Zepbound, or Foundayo for eligible Medicare Advantage members, effective July 1, 2026) applies only to Medicare Advantage plans. HMSA commercial members are not eligible for this program. See Humana HI pages for Medicare Advantage GLP-1 coverage details.

Hawaii Electronic Prescribing (EPCS) and Weight Loss Medications

Hawaii’s electronic prescribing for controlled substances (EPCS) law, HRS § 329-38.5, requires electronic prescribing for Schedule II controlled substances only. This has a significant impact on how weight loss medications may be prescribed in Hawaii:

• GLP-1 medications (Wegovy, Zepbound, Saxenda, Ozempic, Mounjaro): Non-scheduled (not controlled substances) — EPCS is entirely inapplicable. Providers may prescribe via paper, phone, fax, or electronic means.
• Contrave (naltrexone/bupropion ER): Non-scheduled — EPCS inapplicable.
• Orlistat: Non-scheduled — EPCS inapplicable.
• Phentermine (generic): Schedule IV controlled substance — NOT subject to Hawaii’s EPCS mandate. HRS § 329-38.5 covers Schedule II only. Providers in Hawaii may prescribe phentermine via paper or electronic means without triggering the EPCS requirement. This differs from West Virginia, where W. Va. Code § 60A-4-403a covers all controlled substances including Schedule IV, requiring EPCS for phentermine in WV.
• Qsymia (phentermine/topiramate ER): Schedule IV — similarly NOT subject to HI EPCS (Schedule II only). Note: Qsymia has a separate FDA REMS (Risk Evaluation and Mitigation Strategy) program that requires prescriber certification, but this is a federal FDA requirement, not a state EPCS requirement.

In practical terms, for Hawaii providers and patients: all commonly prescribed weight loss medications — including Schedule IV phentermine and Qsymia — may be prescribed without mandatory electronic prescribing under Hawaii law. GLP-1s and oral agents like Contrave and orlistat face no controlled substance prescribing restrictions whatsoever in Hawaii.

Does Hawaii’s Mental Health Parity Law Cover Weight Loss Treatment?

Hawaii’s mental health parity law, Haw. Rev. Stat. § 431M-1 et seq., requires insurers to provide mental health and substance use disorder (MH/SUD) benefits on parity with medical/surgical benefits. This law does not govern weight loss treatment, which is a medical/surgical service and not a mental health or substance use disorder benefit.

Weight loss coverage in Hawaii is instead governed by:

• ACA Essential Health Benefits (EHB): ACA marketplace plans are required to cover preventive obesity counseling (intensive behavioral therapy for adults with BMI ≥30, per USPSTF recommendations) at no cost-sharing. However, ACA does not universally mandate coverage of prescription weight loss medications.
• Plan design and employer decisions: Employer-sponsored plans (both fully insured and self-funded) have broad discretion over whether to include weight loss medication coverage. Many large employers have added GLP-1 coverage in 2025–2026, but coverage is far from universal.
• ERISA preemption: Self-funded employer plans are governed by ERISA and are not subject to Hawaii’s state insurance mandates. Federal MHPAEA still applies to self-funded plans, but only for MH/SUD benefits — not weight loss coverage.

If your HMSA plan denies weight loss medication coverage on the basis that it is not a covered benefit (rather than not meeting medical necessity criteria), review your Summary Plan Description (SPD) or Evidence of Coverage (EOC) and consult with an HMSA member advocate at 1-800-776-4672.

Hawaii Prepaid Health Care Act and Weight Loss Coverage

Hawaii’s Prepaid Health Care Act (HRS § 393) is a unique state law that requires employers with employees working 20 or more hours per week to provide health insurance coverage. This is why employer-sponsored health insurance enrollment rates in Hawaii are among the highest in the nation.

Key points regarding the Prepaid Health Care Act and weight loss coverage:

• The Act mandates employer-sponsored health coverage but does not dictate specific benefit designs. It does not require employers to cover prescription weight loss medications.
• Weight loss medication coverage remains a plan design decision made by the employer and/or HMSA under the employer’s contract — not a state mandate under HRS § 393.
• The ACA (federal law) and ERISA (for self-funded plans) are the primary federal frameworks governing what must be covered for weight loss treatment.
• For questions about employer obligations under the Prepaid Health Care Act, contact the Hawaii Department of Labor and Industrial Relations (DLIR) at 1-808-586-8777 or visit labor.hawaii.gov.

What Weight Loss Services May HMSA Cover?

In addition to prescription weight loss medications (subject to the formulary and PA requirements above), HMSA may cover the following weight loss-related services depending on your plan:

• Preventive obesity counseling: Intensive behavioral therapy (IBT) for obesity is a USPSTF Grade B recommendation covered without cost-sharing on ACA-compliant plans. This typically includes dietary assessment, behavioral counseling, and physical activity guidance.
• Medical evaluation: Visits with a primary care provider or obesity medicine specialist to establish BMI documentation and comorbidities (required for PA).
• Telehealth weight loss visits: HMSA may cover telehealth visits for weight management consultations and medication management, including GLP-1 prescribing via telehealth.
• Nutritional counseling: Medical nutrition therapy may be covered for members with obesity-related conditions such as type 2 diabetes or cardiovascular disease.
• Bariatric surgery: Bariatric procedures (gastric bypass, sleeve gastrectomy) may be covered under some HMSA plans for members meeting clinical criteria (typically BMI ≥40 or ≥35 + severe comorbidity, with documented behavioral program participation).
• Prescription weight loss medications: GLP-1s (Wegovy, Zepbound, Saxenda), Contrave, orlistat, phentermine, and Qsymia subject to the formulary tiers and PA criteria above.

How to Verify Your HMSA Weight Loss Coverage

Because weight loss benefit design varies significantly by employer and plan, the most reliable approach is to verify your specific coverage before starting treatment:

1. Review your Summary Plan Description (SPD) or Evidence of Coverage (EOC): Look for sections on “weight management,” “obesity treatment,” or “prescription drug benefits.” These documents specify what your employer has included or excluded.
2. Call HMSA member services: Call 1-800-776-4672 and ask specifically whether your plan covers GLP-1 weight loss medications and whether prior authorization is required. Ask for a coverage determination in writing.
3. Check the CVS Caremark formulary: Visit cvs.com/drug/list or call CVS Caremark at 1-866-488-4708 with your HMSA member ID to confirm the tier placement and PA requirements for specific medications.
4. Request prior authorization in advance: Work with your provider to submit a PA request before starting a GLP-1 medication. Your provider can submit through prc.hmsa.com or by calling 1-866-488-4708.
5. If denied, appeal: HMSA is required to provide a written denial with the specific clinical or benefit criteria not met. You have the right to a first-level internal appeal and, if unsuccessful, an external independent review under Hawaii law and the ACA.

How Klarity Health Can Help

Klarity Health has a network of 2,000+ licensed providers across Hawaii and other states who specialize in weight management treatment. Our providers are experienced with GLP-1 medications, prior authorization requirements, and HMSA/CVS Caremark coverage criteria. If you are interested in exploring whether Wegovy, Zepbound, or other FDA-approved weight loss medications may be right for you:

Check if your HMSA plan may cover weight loss treatment through Klarity Health

Our team can help with medical evaluation, documentation for prior authorization, and ongoing medication management — all available via telehealth for Hawaii residents.

Frequently Asked Questions

Does HMSA cover Wegovy in Hawaii?

HMSA may cover Wegovy (semaglutide 2.4 mg) for weight management under some plans. Coverage is typically at Tier 3–4 on the CVS Caremark formulary and generally requires prior authorization with documentation of BMI ≥30 (or ≥27 with a comorbidity) and often a referral or enrollment in behavioral weight loss counseling. Whether your specific plan includes Wegovy coverage depends on your employer’s benefit design — not all HMSA plans cover GLP-1 weight loss medications. Call HMSA at 1-800-776-4672 to verify your plan’s coverage.

Is Zepbound back on HMSA’s formulary in 2026?

Yes, Zepbound (tirzepatide) is being reinstated on CVS Caremark commercial formularies effective October 1, 2026, after a period of removal. HMSA members whose plans use the CVS Caremark commercial formulary may find Zepbound available again at Tier 3–4 with prior authorization. If you were previously denied Zepbound due to the formulary removal, your provider may resubmit a PA request after October 1, 2026. Verify your plan’s current formulary status by calling CVS Caremark at 1-866-488-4708 with your HMSA member ID.

Does HMSA require electronic prescribing for phentermine in Hawaii?

No. Hawaii’s electronic prescribing law (HRS § 329-38.5) requires electronic prescribing for Schedule II controlled substances only. Phentermine is a Schedule IV controlled substance, which means it is not subject to Hawaii’s EPCS mandate. Hawaii providers may prescribe phentermine via paper prescription, phone, or fax without violating HRS § 329-38.5. Note: Qsymia (phentermine/topiramate ER) is also Schedule IV and not subject to HI EPCS, though it has a separate FDA REMS certification requirement for prescribers.

Does Hawaii’s parity law require HMSA to cover weight loss medications?

No. Hawaii’s mental health parity law, Haw. Rev. Stat. § 431M-1 et seq., requires parity between mental health/substance use disorder benefits and medical/surgical benefits. It does not govern weight loss treatment, which is a medical/surgical benefit determined by plan design, ACA Essential Health Benefits requirements, and employer decisions. Weight loss medication coverage is not mandated by Hawaii state law for commercial insurance plans.

Does the Medicare GLP-1 Bridge apply to my HMSA plan?

No. The CMS Medicare GLP-1 Bridge (effective July 1, 2026, providing $50/month access to Wegovy, Zepbound, or Foundayo for eligible Medicare Advantage MAPD members) applies only to Medicare Advantage plans. HMSA commercial members — including those with individual, group, or employer-sponsored HMSA coverage — are not eligible for this program. If you have a Humana Medicare Advantage plan in Hawaii, consult Humana’s resources for the GLP-1 Bridge details.

What happens if HMSA denies my weight loss medication request?

If HMSA or CVS Caremark denies a weight loss medication PA request, you will receive a written Explanation of Benefits (EOB) stating the denial reason. Your options include: (1) First-level internal appeal with HMSA within 180 days of the denial — request this in writing and ask your provider to submit additional clinical documentation. (2) Independent medical review (IMR) — if the internal appeal is unsuccessful and the denial involves medical necessity, you may request an external independent review by an organization contracted with the Hawaii Insurance Division. (3) If the issue is a benefit exclusion (not a medical necessity determination), consult with your employer’s HR department, as they may have discretion to authorize coverage. Contact the Hawaii Insurance Division at 1-808-586-2790 or insurance.hawaii.gov for regulatory guidance.

Key Contacts

• HMSA Member Services: 1-800-776-4672 | hmsa.com
• CVS Caremark (HMSA PA line): 1-866-488-4708 | prc.hmsa.com
• CVS Caremark (Member line): 1-800-552-8159 | cvs.com
• Hawaii Insurance Division: 1-808-586-2790 | insurance.hawaii.gov
• Hawaii DLIR (Prepaid Health Care Act): 1-808-586-8777 | labor.hawaii.gov
• SAMHSA National Helpline: 1-800-662-4357 (24/7 mental health and substance use referrals)
• 988 Suicide and Crisis Lifeline: Call or text 988
• Klarity Health: helloklarity.com/service/weight-loss

Disclaimer: This article is for informational and educational purposes only and does not constitute medical, legal, or insurance advice. Coverage information reflects general CVS Caremark commercial formulary patterns as of July 2026 and may not reflect your specific HMSA plan design. Coverage varies by plan, employer, and individual medical circumstances. Always verify your benefits directly with HMSA and CVS Caremark before starting any treatment. Klarity Health is not affiliated with HMSA, CVS Caremark, or the Blue Cross Blue Shield Association. Self-funded employer plans administered by HMSA are governed by ERISA and may not be subject to Hawaii state insurance mandates. Patients should consult a licensed healthcare provider for individualized medical advice.